Alembic Pharma on Thursday announced its financial results for the second quarter ending 30th September 2024. According to the company’s statement, it reported a 25% increase in Profit Before Tax (PBT), amounting to ₹168 crore. Net sales grew by 3% to reach Rs.1,648 crore, while EBITDA rose by 18% to Rs.257 crore, resulting in an EBITDA margin of 15.6%. Net profit increased by 12%, amounting to Rs.153 crore.
The strong performance was attributed to enhanced execution capabilities within India’s Branded Business, particularly in the Specialty and Animal Health segments. During the quarter under review, the USFDA inspected the company’s Oncology Formulation Facility (F-2), which was completed without any Form 483 observations.
The India Branded Business saw a growth of 6% to Rs.609 crore for the quarter. The company recorded strong growth in its speciality therapies, with 8% growth in gynaecology, 11% in cardiology, 18% in anti-diabetic, and 13% in ophthalmology.
The animal health segment reported a 20% growth driven by a robust portfolio of strong brands. Alembic also launched three new products during the quarter.
“India’s Branded Business continues to enhance execution capabilities in both quality and scale, with the Specialty and Animal Health segments showing good growth. The USFDA successfully inspected our Oncology Formulation Facility (F-2) without any form 483 observations,” Shaunak Amin, MD, Alembic Pharmaceuticals Limited said.
In the international business, the US Generics division grew by 5%, contributing Rs.467 crore, with eight new product launches in the US market. Ex-US International Formulations grew by 18%, reaching Rs.298 crore. During the quarter, Alembic received nine ANDA approvals, bringing the total to 214.
However, the API business saw a decline of 15% to ₹274 crore for the quarter.
